Sexually-transmitted infection (STI) - May 24, 2022

Three crucial tests, One new assay

Three crucial tests, One new assay

Back in January 2022, BD introduced the new BD CTGCTV2 for BD MAX™ System to simultaneously test for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV) in one assay, with one patient sample. These three pathogens represent the most prevalent non-viral sexually-transmitted infections (STIs).

After a 6-month transition, this newly CE marked assay will fully replace the BD MAX™ CT/GC/TV as of end of June in Europe, Middle East and Africa.

Our new assay allows for greater flexibility, performance and diagnostic accuracy in STI testing by:

  • Eliminating the pre-warm step used in the BD MAX™ CT/GC/TV assay for a 30-minute shorter time to results
  • Requiring 2 gene targets for positive GC results
  • Performing male TV testing with urine specimens

In addition, BD has also launched new separated collection device options (swab and urine) validated for use with the BD CTGCTV2 / BD CTGC2 assays and with the BD MAX™ Vaginal Panel (swab only). For an even easier workflow, the new collection devices will be delivered with a pierceable reclosable septum cap and the BD CTGCTV2 for BD MAX™ System remains rack and run compatible with most of the assays available on BD MAX™ System.

Get an exclusive sneak peek at the BD CTGCTV2!


By reading this content you are acknowledging our forward looking statement.

Why join BD MAX™ Club?

Connect with professionals from around the world BD MAX™ Club members represent a community of professionals in infectious diseases and molecular diagnostics. With regional meet-ups and live webinars from global experts, expand your laboratory’s network and collaborate with worldwide colleagues.

Tailored medical and technical expertise Whether you need compelling scientific research or tutorials for troubleshooting on the BD MAX™ System, BD MAX™ Club is here to accompany your molecular diagnostics journey. Sign up now as a BD MAX Club member, to stay in the know of scientific updates and upcoming event(s).

Exclusive members’ perks BD MAX™ Club membership unlocks doors to exclusive webinars and collaboration with industry leading experts. Engage with your colleagues in the molecular community and exchange with the BD research and development team.

Latest news

Forward Looking Statement

The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures.

All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company’s control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.